![\"Tony](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/a800c19d1142d6b1071c65afbbe10281-1790934208.jpeg\")
STV NewsTony hopes the drug will help slow the progression of the disease STV News<\/p>\nScientists in Dundee are spearheading a new drug that could revolutionise treatment for people with Parkinson\u2019s disease.<\/p>\n
For decades, treatments for the progressive brain disorder, have focused on managing symptoms rather than slowing progression of the disease.<\/p>\n
Researchers at the University of Dundee are now participating in an international clinical trial exploring whether a more personalised approach which identifies and treats patients based on the underlying biology driving their disease, could help change that.<\/p>\n
Tony Hindhaugh, who lives in Ullapool, was diagnosed with Parkinson\u2019s in 2025 at the age of 55.<\/p>\n
After undergoing a series of genetic testing to determine his eligibility, he is now taking part in the global clinical trial of NEULARK.<\/p>\n
\u201cThe reason I wanted to get involved with this trial is that it is specific, very direct and very targeted,\u201d he said. \u201cI understand everything about it with regards to how the targeted medication could be a lot better to my specific problem.<\/p>\n
\u201cMy Parkinson\u2019s symptoms are very mild. At present, the tremor is the only thing that gives it away. But while it hasn\u2019t interrupted anything in my life at the minute, it has made me think and slow down a bit.<\/p>\n
STV NewsTony hopes the drug will help slow the progression of the disease STV News<\/p>\n
\u201cI\u2019m not taking Levodopa yet. I know it\u2019s seen as the standard medication for many, but I see that as something that is way down the track for me. I don\u2019t want to take a medication that covers up my symptoms and allows me to carry on blindly for the time being.<\/p>\n
\u201cI\u2019m a logical person and this trial appeals to me because there are some very educated academics behind trying to look at the nuances in Parkinson\u2019s and address those.<\/p>\n
\u201cOverall, this trial gives me hope. I\u2019m not unrealistic \u2013 I know my Parkinson\u2019s is not going to be cured \u2013 but I fully understand that a targeted medication could be a lot better to a specific problem.<\/p>\n
\u201cAnything that could try and control something which is a clear, known and defined deficiency has merit, and that is why I am fully committed to this process.\u201d<\/p>\n
The trial is evaluating the precision medicine approach in people with LRRK2-driven Parkinson\u2019s disease. Mutations in the gene are the most frequent cause of inherited Parkinson\u2019s disease, triggering cellular dysfunction that leads to the disease.<\/p>\n
Unlike traditional \u201cone-size-fits-all\u201d approaches, the trial is enrolling participants whose genetics suggest they may be more likely to benefit from treatment.<\/p>\n
Researchers at the Dundee Medical Research Council Protein Phosphorylation and Ubiquitylation Unit are among a select group of international sites participating in the study.<\/p>\n
People aged between 40 and 80 years old, who have early Parkinson\u2019s disease could be eligible.<\/p>\n
Professor Dario Alessi from Dundee University is an internationally recognised expert in LRRK2 biology and has dedicated his life to researching Parkinson\u2019s disease.<\/p>\n
\u201cWe managed to uncover a whole new pathway that seems to play a really important role in triggering Parkinson\u2019s, said Professor Alessi.<\/p>\n
\u201cInterestingly the research suggests that the pathway becomes over switched on when you have Parkinson\u2019s and that led to new ideas for drug companies to come in and develop new drugs that would counteract this over switched on enzyme.<\/p>\n
![\"Scientists](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/53b237710f5d5ee0c9e7ad7bf025ba9c-1790933876.jpeg\")
STV NewsScientists developing new drug designed at people with certain genetic profiles STV News<\/p>\n
\u201cEven slowing the disease down would be huge because it would buy patients a lot more time to continue doing the things they enjoy doing. That would be the first step, if we can slow it down, then you can slow it down better, then you can stop it, then you can reverse it and then you can maybe prevent it from happening in the future.\u201d<\/p>\n
Dr Esther Sammler is the Principal Investigator of the Dundee NEULARK clinical trial site.<\/p>\n
\u201cYou may already be familiar with the concept of personalised medicine or precision medicine from all other fields of medicine, from cancer for example, where matching the right participant with the right intervention is key to success. This is now more and more explored in neurodegenerative diseases and Parkinson\u2019s disease.\u201d<\/p>\n
More than 150,000 people in the UK are living with Parkinson\u2019s disease, yet there are currently no approved therapies that slow disease progression.<\/p>\n
The NEULARK trial, sponsored by Neuron23<\/a>, is evaluating whether targeting the LRRK2 pathway in patients with evidence of LRRK2 overactivity may offer a more personalised approach than has historically been possible.<\/p>\n STV News is now on WhatsApp<\/p>\n Get all the latest news from around the country<\/p>\n
![\"WhatsApp](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/1791213012_77_whatsapp-qr.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"Scientists in Dundee are spearheading a new drug that could revolutionise treatment for people with Parkinson\u2019s disease. For…\n","protected":false},"author":2,"featured_media":792769,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[59,102,56,54,55],"class_list":["post-792768","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-gb","tag-health","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/792768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=792768"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/792768\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/792769"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=792768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=792768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=792768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}